Member Info for TRENCH123

We have a confident CEO who is looking to deliver big change here and is excited with the progress being made

I am happy to trust that he will deliver well in the coming months, regardless of the historical data

As you correctly say, nothing is priced in at the moment. Plenty of upside to look forward to IMHO

Avocet, loss making businesses within the industry are common, but this does not mean they have no value

As an example, Bicycle Therapeutics had sales of £35m and a net loss of £182m in the year to 31st December 2024 but currently has a market capitalisation around £500m. It is down to future potential

Should a commercial deal be reached with DosemeRx then a serious re-rate will kick in. I would fully expect a draft agreement to be already in place with DosemeRx , ready to be signed off on successful completion of the final testing of the tool

Worst, please stick to relevant posts regarding PYC the company Don't be so childish

There is plenty of interest. Nearly 45% of PYC shares in issue were traded in a single day recently

Hitesh is a very clever guy. Good to have him on board with PYC

PYC have excellent data resources and a proven track record on delivery of high quality results for reputable customers.

They are well positioned to cash-in IMHO

This is the 'AI Overview' generated from my google search on 'AI g-csf physiomics'

Physiomics is leveraging AI to develop and improve G-CSF dosing strategies in cancer treatment, particularly for personalized chemotherapy management. Their AI-powered tools aim to optimize G-CSF dosing, reduce the risk of chemotherapy-induced neutropenia (CIN), and personalize chemotherapy regimens for individual patients. This approach can lead to fewer hospital admissions, reduced side effects, and potentially improved treatment outcomes.

Key aspects of Physiomics' AI-driven approach to G-CSF and chemotherapy:

• Personalized Chemotherapy Dosing: Physiomics' AI tools help oncologists determine the optimal chemotherapy dose for each patient, taking into account individual factors to minimize side effects and maximize treatment effectiveness.

• Optimizing G-CSF Dosing: By predicting a patient's risk of neutropenia, the AI can help optimize the timing and dosage of G-CSF (Granulocyte Colony-Stimulating Factor) to prevent severe infections and reduce the need for hospitalization.

• Reducing CIN Risks: Chemotherapy-induced neutropenia (CIN) is a serious side effect of cancer treatment. Physiomics' AI-powered tools aim to minimize the risk of CIN by optimizing chemotherapy and G-CSF dosing.

• Home-Based Testing: The company's "Beyond Blood" platform allows for convenient home-based blood testing, facilitating faster results and earlier interventions for neutropenia.

• Predictive Modeling: Physiomics uses mathematical models and data science to predict patient outcomes and optimize treatment strategies, including G-CSF dosing.

• Collaboration and Partnerships: Physiomics collaborates with pharmaceutical companies and hospitals to integrate its AI-powered tools into clinical workflows and research projects.

In essence, Physiomics is using AI to transform cancer treatment by personalizing chemotherapy and G-CSF dosing, leading to safer and more effective cancer care.

Statler and Waldorf aka ilovesushi and jaari are back again, as expected

We’re heading to ASCPT 2025 in Washington DC, 28-30th May! As specialists in PKPD modelling, QSP and biostatistics, we help pharma and biotech teams make smarter, faster development decisions

'Lifestyle company' it is nothing of the sort IMHO

Had it not been for Covid and the further delays following the change in ownership of DosemeRx then I believe we would be now be seeing cash flows from a commercial deal and a much stronger financial position

PS remarked late last year that PYC are making 'great progress' on their dosing tool and at the last IMC presentation JM indicated that as the project 'matures' then 'there may be some metrics that we can release .... about the scale of the opportunity over there (in the US) that we see'

Significant news could appear at any time

King H some excellent points made. Thanks

Sorry, was dashing out and made a bit a horlicks of the post. Maybe you get the gist

Please all, lets keep to posting about news released, to be released etc and not get distracted by endless argument

PYC is a professionally run company, lets keep the share chat to a respectable level too

I'm all for constructive argument but sometimes the same points get debated ad infinitum

and not clutter up the board with pointless personal

argument which gets us nowhere

Https://weatherden.co.uk/blog/dose-matters-part-one

This is an excellent endorsement of the work of PYC. Dr Simon Hutchings, one of the Weatherden team involved in the joint release, is also on the SAB of Simbec-Orion

With more to follow, this collaboration could prove very interesting

Welcome news. Will give a boost to the June year-end figures

The silence from the BOD is not doing the share price any favours. I cannot understand why there is no attempt to promote the company at the present time

PS mentioned the cost of listing on AIM in the last investor presentation. Unlikely, but just hope the company are not considering taking the company private and de-listing on AIM. That would be a real kick in the teeth to loyal investors. Certainly the drop in share price to well below the recent placing price is a worry. Could there be a leak which is causing the continuing sell off - sadly, nothing can ever be ruled out on AIM

More likely a positive update is on the way providing news on the DosemeRx partnership, G-CSF project or new contracts. Let's hope so

It has been extremely noticeable that PYC have significantly curtailed their PR activity on both X and Linkedin recently. Only one post on X in the last month and weekly posts on Linkedin whereas previously almost daily activity was the norm. Similarly, the regular newsletter not seen for some months now would appear to have been shelved, at least for the time being

At a time when PYC need all the exposure they can get this would appear to be a very strange policy. Maybe the people normally involved in PR work within the company are too busy on paid work, which would be possible given the comments by PS at the recent investor presentation

Just maybe the management are in the process of entering into a big deal to sell the company or finalising important contracts/agreements. Suggestions are that something is underfoot. Be it good or bad - time will tell

There are many reasons why stock is sold at seemingly odd prices. Take our major shareholder here who sold a chunk at short notice due to urgent business needs for his cash. The negative effects of the Trump tariffs on markets generally may also indirectly be a factor here

The likelihood on any future revenue from the Valirx agreement is clearly much less likely following today's news

The agreement was not specifically linked to TheoremRx so revenue could still be forthcoming if another party gets involved and a deal is struck

KH - thanks for reminding everyone of the real potential here